Considering its crucial role, HDAC4 has been proposed as a potential therapeutic target for diseases characterized by neurogenic muscle atrophy, such as ALS or SMA, or for sarcopenia [36–39]. This evidence concerns the gene HDAC4 and Skeletal muscle atrophy.